
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Optimapharm, an independent clinical research organization (CRO), acquired Denothex Ltd. Optimapharm operates in offices across 14 European countries. It covers markets with a total population of over 500 million people, and conducts phase I – IV clinical research across Europe with a very strong footprint in Central and Eastern Europe.
Read the full release






